Glaucoma, apoptosis y sildenafil: comprensión de una enfermedad sin solución y un posible enfoque de tratamiento
Comprensión de una enfermedad sin solución y un posible enfoque de tratamiento
Palabras clave:
Apoptosis, Glaucoma, Células ganglionares de la retinaResumen
Millones de pacientes con glaucoma pierden la visión, por lo que es una necesidad para
desarrollar terapias neuroprotectoras que pueden utilizarse en conjunción con medicamentos
hipotensores, para prevenir la muerte de las células ganglionares de la retina (CGR). Los
recientes avances en la comprensión de la fisiopatología de glaucoma es un factor clave en la
patogénesis de la neuropatía glaucomatosa. Con base en los hallazgos en enfermedades
similares, la hipótesis de que la mejora del flujo sanguíneo de la retina nervio óptico puede
dar lugar a una protección significativa en CGR y prevenir la pérdida de visión en el
glaucoma. Sildenafil, un fármaco vasodilatador que inhibe la PDE5, lo que aumenta los
niveles de cGMP y la prolongación de sus efectos, y se ha demostrado que mejora la
supervivencia de diversas lesiones degenerativas. Esta breve revisión resume los avances más
importantes que tenían el conocimiento de esta enfermedad y su posible tratamiento.
Citas
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-7.
Sakata K, Sakata LM, Sakata VM, Santini C, Hopker LM, Bernardes R, et al. Prevalence of glaucoma in a South brazilian population: Projeto Glaucoma. Invest Ophthalmol Vis Sci. 2007;48:4974-9.
Leske MC. Open-angle glaucoma: an epidemiologic overview. Ophthalmic Epidemiol. 2007;14:166-72.
Duggal P, Klein AP, Lee KE, Iyengar SK, Klein R, Bailey-Wilson JE, et al. A genetic contribution to intraocular pressure: the beaver dam eye study. Invest Ophthalmol Vis Sci. 2005;46:555-60.
Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. Pharmacoeconomics. 2007;25:287-308.
Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF. Neuroprotection in glaucoma - Is there a future role?. Exp Eye Res. 2010;91:554-66.
Hayreh SS, Peer J, Zimmerman MB. Morphologic changes in chronic high-pressure experimental glaucoma in rhesus monkeys. J Glaucoma. 1999;8:56-71.
Nickells RW. From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma. Can J Ophthalmol. 2007;42:278-87.
Lin IC, Wang YH, Wang TJ, Wang IJ, Shen YD, Chin NF, et al. Glaucoma, Alzheimer’s disease, and Parkinson’s disease: an 8-year population-based follow-up study. Plos One.
;9:1-6.
Nickells RW. Ganglion cell death in glaucoma: from mice to men. Vet Ophthalmol. 2007;10:88-94.
Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol. 1989;107:186-8.
Flammer J, Mozaffarieh M. What is the present pathogenetic concept of glaucomatous optic neuropathy? Surv Ophthalmol. 2007;52:S162-73.
Quigley HA. Glaucoma. Lancet. 2011;377:1367-77.
Doganay S, Evereklioglu C, Turkoz Y, Er H. Decreased nitric oxide production in primary open-angle glaucoma. Eur J Ophthalmol. 2002;12:44-8.
Reichstein D, Ren L, Filippopoulos T, Mittag T, Danias J. Apoptotic retinal ganglion cell death in the DBA/2 mouse model of glaucoma. Expe Eye Res. 2007;84:13-21.
Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res. 2012;31:152-81.
Johnston KC. Effect of sildenafil (Viagra) on cerebral blood vessels. Neurology. 2005;65:785-94.
Orejana L, Barros-Miñones L, Jordán J, Puerta E, Aguirre N. Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model. Neurobiol Aging. 2012;33:625.e11-20.
Serarslan Y, Yönden Z, Ozgiray E, Oktar S, Güven EO, Söğüt S, et al. Protective effects of tadalafil on experimental spinal cord injury in rats. J Clin Neurosci. 2010;17:349-52.
Ozdegirmenci O, Kucukozkan T, Akdag E, Topal T, Haberal A, Kayir H, et al. Effects of sildenafil and tadalafil on ischemia/reperfusion injury in fetal rat brain. J Matern Fetal Neonatal Med. 2011;24:317-23.
Weinreb RN. Glaucoma neuroprotection: What is it? Why is it needed? Can J Ophthalmol. 2007;42:396-8.
Vrabec JP, Levin LA. The neurobiology of cell death in glaucoma. Eye. 2007;21:S11-4.
Ofri R, Dawson WW, Foli K, Gelatt KN. Primary open-angle glaucoma alters retinal
recovery from a thiobarbiturate: spatial frequency dependence. Exp Eye Res. 1993;56:481-8.
Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, Weinreb RN. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol. 2004;138:S19-31.
Plummer CE, Regnier A, Gelatt N. The canine glaucomas. Vet Ophthalmol. 2013;2:1053-4.
Scott EM, Boursiquot N, Beltran WA, Dubielzig RR. Early histopathologic changes in the retina and optic nerve in canine primary angle-closure glaucoma. Vet Ophthalmol. 2013;16:76-86.
Crish SD, Calkins DJ. Neurodegeneration in glaucoma: progression and calciumependent intracellular mechanisms. Neuroscience. 2011;176:1-11.
Flammer J, Orgül S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002;21:359-93.
Grivicich I, Regner A, Rocha AB. Morte cellular por apoptose. Rev Bras Cancerol. 2007;53:335-54.
Luchs A, Pantaleão C. Apoptose e modelos in vivo para estudo das moléculas relacionadas a este fenômeno. Einstein. 2010;8:495-507.
Clavien PA, Rudiger HA, Selzner M. Mechanism of hepatocyte death after ischemia: apoptosis versus necrosis. Int J Oncol. 2000;17:869-79.
Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nature. 2008;9:378-90.
Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. Br J Cancer. 1972;26:239-57. 34. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516.
Zeiss CJ. The apoptosis-necrosis continuum: insights from genetically altered mice. Vet Pathol. 2003;40:481-95.
Lewin AS, Drenser KA, Hauswirth WW, Nishikawa S, Yasumura D, Flannery JG, et al. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med. 1998;4:967-71.
Parolin MB, Reason IJ. Apoptosis as a mechanism of tissue injury in hepatobiliary diseases. Arg Gastroenterol. 2001;38:138-44.
Hanninen VA, Pantcheva MB, Freeman EE, Poulin NR, Grosskreutz CL. Activation of caspase 9 in a rat model of experimental glaucoma. Curr Eye Res. 2002;25:389-95.
Levkovitch-Verbin H, Dardik R, Vander S, Melamed S. Mechanism of retinal ganglion cells death in secondary degeneration of the optic nerve. Exp Eye Res. 2010;91:127-34. 40. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al.
Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727-30.
Kirkland RA, Windelborn JA, Kasprzak JM, Franklin JL. A Bax-induced pro-oxidant state is critical for cytochrome c release during programmed neuronal death. J Neurosci. 2003;22:6480-90.
Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008;7:742-55.
Ning B, Aida T, Yanagisawa M, Katou S, Sakimura K, Mishina M, et al. NMDA receptor subunits have different roles in NMDA-induced neurotoxicity in the retina. Mol Brain. 2013;6:1-9.
Seki M, Soussou W, Manabe S, Lipton SA, et al. Protection of retinal ganglion cells by caspase substrate-binding peptide IQACRG from N-methyl-D-aspartate receptormediated excitotoxicity. Invest Ophthalmol Vis Sci. 2010;51:1198-207.
Sandalon S, Könnecke B, Levkovitch-Verbin H, Ofri R. Functional and structural evaluation of lamotrigine treatment in rat models of acute and chronic ocular hypertension. Exp Eye Res. 2013;115:47-56.
Toda N, Nakanishi-Toda M. Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy. Prog Retin Eye Res. 2007;26:205-38.
Abdollahi M, Bahreini-Moghadam A, Emami B, Fooladian F, Zafari K. Increasing intracellular cAMP and cGMP inhibits cadmium-induced oxidative stress in rat submandibular saliva. Comp Biochem Physiol C Tocicol Pharmacol. 2003;135C:331-6.
Milani E, Nikfar S, Khorasani R, Zamani MJ, Abdollahi M. Reduction of diabetesinduced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol. 2005;140:251-5.
Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol. 2008;294:H1398-406.
Ebrahimi F, Shafaroodi H, Asadi S, Nezami BG, Ghasemi M, Rahimpour S, et al. Sildenafil decreased cardiac cell apoptosis in diabetic mice: reduction of oxidative stress as a possible mechanism. Can J Physiol Pharmacol. 2009;87:556-64.
Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC. Phosphodiesterase-5 inhibition with sildenafil attenuates ardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation. 2005;111:1601-10.
Marmor MF. Sildenafil (Viagra) and ophthalmology. Arch Ophthalmol. 1999;117:518-9.
Koksal M, Ozdemir H, Kargi S, Yesilli C, Tomaç S, Mahmutyazicioglu K, et al. The effects of sildenafil on ocular blood flow. Acta Ophthalmol. 2005;83:355-9.
Lee NPY, Cheng CY. Nitric oxide/nitric oxide synthase, spermatogenesis, and tight junction dynamics. Biol Reprod. 2004;70:267-76.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Este obra está licenciado com uma Licença Creative Commons Atribuição-NãoComercial 4.0 Internacional.
